BeOne Medicines Ltd ADR Dossier
Qualitative Analysis
Business overview
BeOne Medicines Ltd. (NASDAQ: ONC), formerly known as BeiGene, Ltd., is a leading global commercial-stage oncology biotechnology company. Domiciled in Switzerland and headquartered in Basel, the company is dedicated to discovering, developing, and manufacturing innovative cancer treatments that are more affordable and accessible to patients worldwide. BeOne's flagship product is Brukinsa (zanubrutinib), a best-in-class small-molecule Bruton's tyrosine kinase (BTK) inhibitor approved for various B-cell malignancies, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Brukinsa represents the cornerstone of the company's hematology franchise, accounting for over 70% of its product revenue. The company's commercial portfolio also includes Tevimbra (tislelizumab), an anti-PD-1 monoclonal antibody targeting solid tumors, and Beqalzi. BeOne operates a highly integrated global model with clinical trials spanning six continents and a growing manufacturing footprint, including its flagship Princeton West Innovation Campus in the United States.
Research as of 29 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A $300 million expansion of the flagship U.S. manufacturing and clinical R&D hub in Hopewell, New Jersey, bringing the total investment at the site to more than $1 billion.
Expected impact: Supports clinical and commercial-stage biologics manufacturing for the company's solid tumor portfolio and introduces small molecule operations, adding approximately 240 jobs.
Rebranding from BeiGene, Ltd. to BeOne Medicines Ltd., changing the stock ticker to ONC, and redomiciling the corporate headquarters to Basel, Switzerland.
Expected impact: Establishes a unified global identity as a leading multinational oncology company and aligns corporate structure with its global footprint.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
High strategic importance to expand the regulatory submissions and clinical success of TEVIMBRA (tislelizumab) in combination with Jazz's Ziihera in first-line HER2+ gastric cancer.
Terms: Not explicitly disclosed
Medium strategic importance to expand patient support programs, advance patient-focused innovation, and improve access to B-cell cancer therapies.
Terms: Not explicitly disclosed